The pharmacologic profile of 606A, a novel angiotensin II receptor antagonist

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 2, 1997, Pages 284-290

  Hashimoto, Yoshihiro ^a   Harada, Yukie ^a   Narita, Hiroshi ^a   Naito, Kazuaki ^a   Murata, Sakae ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

606A AT1; Angiotensin II antagonist; Angiotensin II receptor; Antihypertensive agent; Insurmountable

Indexed keywords

5 ACETYL 4,5,6,7 TETRAHYDRO 2 PROPYL 3 [2' (1H TETRAZOL 5 YL) 4 BIPHENYLYLMETHYL]IMIDAZO[4,5 C]PYRIDINE 4 CARBOXYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; LOSARTAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CATTLE; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; FEMALE; GUINEA PIG; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; RECEPTOR AFFINITY; SPONTANEOUSLY HYPERTENSIVE RAT;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CATTLE; DOGS; FEMALE; GUINEA PIGS; IMIDAZOLES; LOSARTAN; MALE; RABBITS; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VASOCONSTRICTION;

EID: 0031034476     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199702000-00019     Document Type: Article

References (32)

1. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 1977;57:313-70.
2. Vallotton MB. The renin-angiotensin system. Trends Pharmacol Sci 1987;8:69-74.
3. Ferrario CM. The renin-angiotensin system: importance in physiology and pathology. J Cardiovasc Pharmacol 1990; 15(suppl 3):S1-5.
4. Corvol P, Chauveau D, Jeunemaitre X, Menard J. Human renin inhibitor peptides. Hypertension 1990;16:1-11.
5. Williams GH. Converting enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319:1517-25.
6. Turini GA, Brunner HR, Gribic M, Wacber B, Gavras H. Improvement of chronic congestive heart failure by oral captopril. Lancet 1979;1:1213-5.
7. Cody RJ. Conceptual and therapeutic approaches to inhibition of the renin-angiotensin system in chronic heart failure. J Cardiovasc Pharmacol 1986;8:(suppl 1)S58-65.
8. Gravas H, Gravas I. Angiotensin converting enzyme inhibitors: properties and side effects. Hypertension 1988;11:(suppl II):II37-41.
9. Okunishi H, Miyazaki M, Okamura T, Toda N. Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun 1987;149:1186-92.
10. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348-57.
11. Dzau VJ. Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypotheses. J Hypertens 1989;7:933-6.
12. Smith RD, Chiu AT, Wong PC, Herblin WF, Timmermans PBMWM. Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol 1992;32:135-65.
13. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;252:719-25.
14. Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL. Dose ranging study of the angiotensin type I receptor antagonist losartan (DuP 753/MK954) in salt deplete normal man. J Cardiovasc Pharmacol 1993;21:732-8.
15. MacFadyen RJ, Elliott HL, Meredith PA, Reid JL. Haemodynamic and hormonal responses to low dose enalapril in salt depleted normotensive man. Br J Clin Pharmacol 1993;35:299-301.
16. Stearns RA, Miller RR, Doss GA, et al. The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, human liver slices. Drug Metab Dispos 1991;20:281-7.
17. Wong PC, Price AW, Chiu AT, et al. Nonpeptide angiotetnsin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;255:211-7.
18. Chiu AT, Doncia JV, McCall DE, et al. Nonpeptide angiotensin II receptor antagonists. III. Structure-function studies. J Pharmacol Exp Ther 1989;250:867-74.
19. James PB, Solomon HS. Angiotensin II binding to mammalian brain membranes. J Biol Chem 1976;251:7423-30.
20. 50) of an enzymatic reaction. Biochem Pharmacol 1973; 22:3099-108.
21. Scatchard G. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 1949;51:660-72.
22. Schild HO. pA, A new scale for the measurement of drug antagonism. Br J Pharmacol 1947;2:189-206.
23. Ariens EJ, van Rossum JM. pDx, pAx and pD′x values in the analysis of pharmacodynamics. Arch Int Pharmacodyn 1957;110:275-99.
24. Griendling KK, Lassegue B, Murphy TJ, Alexander RW. Angiotensin II receptor pharmacology. Adv Pharmacol 1994;28:269-306.
25. Bunkenburg B, Van Amelsvoort T, Rogg H, Wood JM. Receptor mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 1992;20:746-54.
26. Wong PC, Timmermans PBMWM. Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonist of EXP3892 is reversed by the surmountable antagonist DuP753. J Pharmacol Exp Ther 1991;258(1):49-57.
27. Beauchanp HT, Chang RSL, Siegl PKS, Gibson RE. In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency. J Pharmacol Exp Ther 1994;272(2):612-8.
28. Timmermens PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45(2):205-51.
29. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991;83:1333-42.
30. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993;35:290-7.
31. van den Meiracker AH, Admiraal PJJ, Janssen JA, et al. Hemodynamic and biological effects of the ATI receptor antagonist irbesartan in hypertension. Hypertension 1995;25:22-9.
32. MacFadyen RJ, Reid JL. Angiotensin receptor antagonists as treatment for hypertension. J Hypertens 1994;12(12):1353-7.